The lithium companies will have to create a new royalty rate proposal, another delay for the commercial extraction of the ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Dividend stocks are providing passive income for millions of investors who use the funds to help meet monthly budgets stressed from inflation.

The lithium companies brought in an army of experts to make the case that their proposed royalty rate is on par with other ...

Uranium Royalty (TSX:URC,NASDAQ:UROY) announced the acquisition of an existing royalty on Cameco’s (TSX:CCO,NYSE:CCJ) ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Choice Hotels' Q3 performance beat expectations, raising the full-year outlook. Learn why CHH stock remains attractive for ...

In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting an increase of 20.3% compared to the same period last year.

Another growth factor is Royalty’s customer attention. “We give them what they want and what they didn’t know they wanted,” Blatt says. That means communicating with customers and spending time with ...

Arm Holdings ( ARM -0.30%) has been a rising star in the semiconductor industry. Its technology is used in half of all chips ...